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Abstract 
A simple, precise and rapid stability-indicating ultra-performance liquid 
chromatography (UPLC) method is developed for the simultaneous quantitative 
determination of Telmisartan, Amlodipine  besylate and Hydrochlorothiazide 
from their innovative poly pill combination drug product in the presence of 
degradation products. It involves a 100 mm x 2.1 mm, 1.7 µm C-18 column. The 
separation is achieved on a simple gradient method. The mobile phase A 
contains a mixture of sodium perchlorate buffer pH 3.2 (0.053M): acetonitrile in 
the ratio 90:10, v/v, and mobile B contains a mixture of sodium perchlorate 
buffer pH 3.2 (0.053M): acetonitrile in the ratio 20:80, v/v. The flow rate is 
0.6 mL min
−1 and the column temperature is maintained at 55°C.The gradient 
program (T/%B) is set as 0/5, 1.2/5, 1.6/40, 4/40, 4.1/5 and 4.5/5. The detector 
wavelength is 271 nm for Hydrochlorothiazide and Telmisartan and 237 nm for 
Amlodipine. The retention times of Telmisartan, Amlodipine, and Hydrochloro-
thiazide are 3.6 minutes, 3.2 minutes and 0.9 minutes; respectively. The total 
runtime for the separation of the three active compounds and their degradation 
products is 4.5 minutes. The described method is validated with respect to 
system suitability, specificity, linearity, precision and accuracy. The precision of 
the assay method is evaluated by carrying out six independent assays of T, A 70 S.  Nalwade  et al.:  
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and H (0.032 mg mL
−1 of T, 0.004 mg mL
−1 of A, 0.01 mg mL
−1 of H). The 
accuracy of the method is evaluated in triplicate at three concentration levels, 
i.e. 50%, 100% and 150% of target test concentration (0.64 mg mL
−1 of T, 
0.08 mg mL
−1 of A, 0.2 mg mL
−1 of H). The described method is linear over the 
range, 16 to 48 µg mL
−1 for T, 2 to 6 µg mL
−1A and 5 to 15 µg mL
−1 for H. The 
method is fast and suitable for high-throughput analysis allowing the analysis of 
about 250 samples per working day. 
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Introduction 
Cardiovascular diseases (CVDs) are the disorders of heart and blood vessels and 
primarily include coronary heart disease, hypertension, cerebrovascular disease, 
peripheral artery disease, rheumatic heart disease, congenital heart disease and heart 
failure. CVDs are the major cause of death in developed countries and also are rapidly 
emerging as a main cause of death in the developing world. An estimated 17.5 million 
people died from CVDs till 2005, representing almost 30% of all the global deaths. It is 
projected that almost 20 million people will die from CVDs by 2015. The major risk factors 
involved in CVDs are high low density lipoprotein (LDL) cholesterol, raised blood pressure, 
increased serum homocysteine level and platelet aggregation, which are primarily caused 
by unhealthy diet, physical inactivity and tobacco use. A novel polypill formulation is 
developed using drugs Telmisartan, Amlodipine besylate and Hydrochlorothiazide for 
CVDs. 
Telmisartan (T) is an angiotensin II receptor (type AT1) antagonist used in the 
management of hypertension. Telmisartan prevents the constriction (narrowing) of blood 
vessels (veins and arteries). Telmisartan is a non-peptide molecule and chemically 
described as potassium 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)-
methyl]biphenyl-2-carboxylate (Fig. 1). 
Hydrochlorothiazide (H) is a thiazide diuretic (water pill) that decreases the amount of fluid 
in the body by increasing the amount of salt and water lost in the urine. Hydrochloro-
thiazide is used to lower blood pressure and to decrease edema (swelling), it is chemically 
described as 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide 
(Fig. 1). 
Amlodipine besylate (A) is in a class of drugs called beta-blockers. Beta-blockers affect the 
heart and circulatory system (arteries and veins). Amlodipine besylate is used to lower 
blood pressure, lower heart rate, reduce chest pain (angina), and to reduce the risk of 
recurrent heart attacks. It is chemically described as 3-ethyl  5-methyl  2-[(2-amino-
ethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate 
benzenesulfonate (Fig. 1). 
The ever-increasing need for speed and efficient use of time in the pharmaceutical and 
other fields, there is demand for the development of fast and high throughput analytical   Rapid Simultaneous Determination of Telmisartan, Amlodipine Besylate and Hydrochlorothiazide …  71 
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procedures. The rapid quantitative determination of combination drugs with big difference 
in label claims (40 mg for T and 5 mg for A) with shorter run times is a challenge. For 
UPLC based assays, the processes of reducing analysis time while adequately resolving 
analytes from degradation products is often accomplished with column with small particles. 
The theoretical advantages for small particles are to get well resolved peaks with high 
theoretical plates over small concentration. 
Present drug stability test guidance Q1A (R2) issued by international conference on 
harmonization (ICH) [1] suggest that stress studies should be carried out on a drug 
product to establish its inherent stability characteristics, leading to identification of 
degradation products and hence supporting the suitability of the proposed analytical 
procedures. It also requires that analytical test procedures for stability samples should be 
stability indicating and they should be fully validated. 
Accordingly, the aim of the present study was to establish inherent stability of Telmisartan, 
Amlodipine besylate, and Hydrochlorothiazide through stress studies under a variety of 
ICH recommended test conditions [1–3] and to develop a rapid stability-indicating reverse 
phase assay method [4–6]. 
Literature survey reveals that a variety of spectrophotometric and chromatographic 
methods including UV, colorimetric determination, ratio derivative, and a stability- 
indicating HPLC methods have been reported for determination T A and H either single or 
in combination with other drugs [7–12]. Whereas no liquid chromatography method has 
been reported for simultaneous quantitative determination of T, A and H in the combined 
dosage form. 
Hence a rapid simple reproducible Ultra performance liquid chromatography method was 
developed for simultaneous quantitative determination of T, A and H in polypill pharma-
ceutical dosage forms in the presence of degradation products.  
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Fig. 1.   Structure of Amlodipine besylate (A), Hydrochlorothiazide (H) and  
Telmisartan (T) 
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Experimental 
Chemicals and reagents 
Standards and tablets (40 mg of Telmisartan, 5 mg of Amlodipine besylate, 12.5 mg of 
Hydrochlorothiazide) were supplied by Dr. Reddy’s laboratories limited, Hyderabad, India. 
The HPLC grade acetonitrile and methanol, analytical grade sodium per chlorate and 
disodium hydrogen phosphate were purchased from Merck, Darmstadt, Germany. Water 
was prepared by using Millipore MilliQ Plus water purification system  
Instrumentation 
Acquity UPLC
TM system (Waters, Milford, USA) used consisting of a binary solvent 
manager, a sample manager and a UV detector. The out put signal was monitored and 
processed using empower software, water bath equipped with MV controller (Julabo, 
Seelbach, Germany) was used for hydrolysis studies. Photo stability studies were carried 
out in a photo stability chamber (Sanyo, Leicestershire, UK). Thermal stability studies were 
performed in a dry air oven (MACK Pharmatech, Hyderabad, India). 
Chromatographic conditions 
The chromatographic column used was Acquity UPLC BEH shield RP-18, 100 mm x 
2.1  mm i.d with 1.7 µm particles. The mobile phase A contains a mixture of sodium 
perchlorate buffer pH 3.2(0.053M): acetonitrile (90:10, v/v) and mobile phase B contains a 
mixture of sodium perchlorate buffer pH 3.2(0.053M): acetonitrile (20:80, v/v). The flow 
rate was 0.6 mL min
−1 and column temperature was maintained at 55°C. The detection 
wavelength was 271 nm for Hydrochlorothiazide and Telmisartan, and 237 nm for 
Amlodipine besylate. The diluent contains a mixture of sodium perchlorate buffer pH 
3.2(0.053M): methanol in the ratio 90:10, v/v. 
Preparation of standard solutions 
Stock standard solutions of T, A and H (0.54 mg mL
−1 of T, 0.2 mg mL
−1 of A, 0.5 mg mL
−1 
of H) were prepared by dissolving an appropriate amounts of the compounds in methanol. 
Working solutions 0.032 mg mL
−1 of T, 0.004 mg mL
−1 of A, 0.01 mg mL
−1 of H were 
prepared from above stock solution in mobile phase for assay determination. 
Preparation of sample solution 
Weighed and crushed twenty tablets into a clean and dry mortar-pestle. An equivalent to 
20 mg of H (64 mg of Telmisartan, 8 mg of Amlodipine besylate) was transferred to a 100 
mL volumetric flask, added 15 mL of 0.1% orthophosphoric acid and kept on rotary shaker 
for 20 minutes. Added 50 mL of methanol and sonicated for 20 minutes. Made the volume 
to 100 mL with methanol (0.64 mg mL
−1 of T, 0.08 mg mL
−1 of A, 0.2 mg mL
−1 of H). About 
5 mL of supernant solution was taken and diluted to 100 mL with diluent to get working 
concentrators (0.032 mg mL
−1 of T, 0.004 mg mL
−1 of A, 0.01 mg mL
−1 of H). The solution 
was then filtered through 0.45 µ (Nylon 66- membrane) filter. 
 
   Rapid Simultaneous Determination of Telmisartan, Amlodipine Besylate and Hydrochlorothiazide …  73 
Sci Pharm. 2011; 79: 69–84 
Results and Discussion 
Chromatographic Method Development 
The method was optimized to separate major degradation products formed under different 
stress conditions. The main target of the chromatographic method is to get the separation 
for closely eluting degradation products, mainly the degradation product at 1.26 RRT (with 
respect to A) that is eluting between A and T. The degradation samples were run using 
different stationary phases like C18, C8, and Mobile phases containing buffers like 
phosphate and perchlorate with different pH (2.5–7) and using organic modifiers like 
acetonitrile and methanol in the mobile phase. The isocratic method was not working since 
telmisartan and amlodipine peaks were not separated with a proper resolution and also the 
degradents of hydrochlorothiazide were not separating from three actives. Hence the 
method is optimized with a gradient program. As the concentration of amlodipine is very 
less as compared to telmisartan, so that to improve response, resolution and peak shapes 
the method was tried at different column temperatures. But the separation, response of 
peaks and peak shapes were satisfactory in the adopted chromatographic conditions only. 
It indicated that the gradient method with 10% acetonitrile as organic modifier in mobile 
phase A and 80% in mobile phase B was successful in separating drugs and all 
chromatographic degradation products. Some of the trials were summarized as below. 
Selection of Diluent (Extracting solvent): 
As the tablets are film coated,and all the active drugs are stable in acidic conditions, the 
0.1% orthophosphoric acid is added in order to open the film coating and to use the same 
assay method for quantification of uniformity of dosage units by UPLC.The trials were 0.1 
N HCl also but the peak shapes are not good in 0.1N HCl. The chromatograph shown in 
Fig.2a. As all the three actives T, A, & H are freely soluble in methanol, so it is used as the 
extracting solvent.  
 
 
Fig. 2a.   Chromatogram of T, A and H at 271 nm and 237 nm from drug product, as 0.1 
N HCl used in the sample preparation instead of 0.1 % OPA 
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Selection of Stationary Phase: 
The stationary phases like C8 and C18 were tried but on C8 the peak shape for T and the 
peak symmetry factor for hydrochlorothiazide is more than 1.7, the separation between A 
and T is not adequate as shown in Fig.2b. On the other hand the peak shapes for all the 
three components are good and all the three peaks are well separated from each other 
and their degradents. So that the column with C18 stationary phase is selected. 
 
Fig. 2b.   Chromatogram of T, A and H at 271 nm and 237 nm from drug product by using 
100 mm x 2.1 mm, 1.7 µm C-8 column with gradient program as 0/5, 1.0/5, 
1.2/40, 3/40, 3.3/5 and 4.0/5.  
Selection of mobile phase buffer: 
The buffers like Phosphate buffer With Buffer with pH 3.2, pH 7.5 and the perchlorate 
buffer with pH 2.5 and 3.2 were tried as mobile phase buffer. But with pH 2.5, pH 7.5 
phosphate and per chlorate buffer with pH 2.5 the results were not enough good in terms 
of peak separation and peak shapes, shown in Fig. 2c. On the other hand the perchlorate 
buffer with pH 3.2, the results were found satisfactory so that the mobile phase with pH 3.2 
perchlorate buffer is finalized. 
Optimization of gradient program: 
Before going to gradient program, an isocratic program with organic modifier methanol and 
acetonitrile were tried but all the three components are eluted at the same retention time 
with both methanol and acetonitrile. As we are using the column temperature 55°C the 
acetonitrile is preferred as an organic modifier rather than methanol. The different gradient 
programs tried are shown in the Fig. 2d. 
Finalization of Chromatographic conditions 
By considering all the experiments the chromatographic conditions are finalized. The 
chromatograph with finalized chromatographic condition was shown in the Fig.3.  
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Fig. 2c.   Chromatograms of T, A, and H from drug product by using different mobile 
phase buffers. 
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Fig. 2d.   Chromatograms of T, A, and H from drug product by using different gradient 
programs. 
Further the analysis was performed for pharmaceutical dosage forms of both the label 
claim tablets (40 mg T, 5 mg A, 12.5 mg H and 20 mg T, 2.5 mg A, 6.25 mg H). The assay 
(% of active drug content present in the tablets with respect to its label claims) results for 
drug product, 99.8%, 99.5%,of T, 99.7%, 98.8% of A and 100.1%, 99.8% of H, 
respectively. 
Analysis also performed (n = 3) separately for Telmisartan, Telmisartan and Hydrochloro-
thiazide tablets and Amlodipine besylate and Hydrochlorothiazide tablets. The assay 
results for Telmisartan were 99.5%, 99.7%, 99.9%. The assay results for Telmisartan and 
Hydrochlorothiazide were, 99.7%, 99.5% and 99.9% for Telmisartan and 99.3%, 98.5% 
and 99.1% for Hydrochlorothiazide. The assay results for Amlodipine besylate and 
Hydrochlorothiazide were, 99.5%, 99.7% and 98.7% for Amlodipine besylate and 99.8%, 
98.5% and 99.3% for Hydrochlorothiazide. It indicated that, adopted UPLC method also 
can be used separately for assay estimation of Telmisartan tablets, simultaneous 
estimation of Telmisartan and Hydrochlorothiazide tablets and simultaneous estimation of 
Amlodipine besylate and Hydrochlorothiazide tablet.   Rapid Simultaneous Determination of Telmisartan, Amlodipine Besylate and Hydrochlorothiazide …  77 
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Fig. 3.  Typical chromatogram of Telmisartan, Amlodipine besylate and 
Hydrochlorothiazide at 271 nm and 237 nm from drug product. 
Method validation 
System suitability 
In order to find the adequate peak separation (resolution) and repeatability of the proposed 
method, suitability parameters including retention factor, selectivity and asymmetry factor 
were investigated and the results were abridged in Table 1. 
Specificity 
The specificity of an analytical method is the ability of the method to determine the analyte 
response in the presence of additional components such as impurities, degradation 
products and matrix [4]. The solution of analytical placebo (containing all the excipients 
except T, A, & H) was prepared according to the sample preparation procedure and 
injected. To identify the interference by these excipients, a mixture of inactive ingredients, 
standard solutions, and the commercial pharmaceutical preparations including T, A, and H 
were analyzed by the developed method. 
The specificity of the method was also evaluated to ensure there were no interference 
products resulting from forced degradation. 
Placebo Interference 
The placebo (excepients present in the tablet) sample were prepared as per the test 
method and analyzed in the UPLC. The Fig.4. shows there is no peaks at the retention 
time of the T, A, & H in the chromatograph indicates that there is no placebo interference. 78 S.  Nalwade  et al.:  
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Fig. 4.  Typical chromatogram of Telmisartan, Amlodipine besylate and Hydrochloro-
thiazide tablets placebo blend at 271 nm and 237 nm from drug product 
Forced degradation studies. 
Stress testing of a drug substance can help to identify the likely degradation products, 
which can help to establish the degradation pathways and the intrinsic stability of the 
molecule. 
All stress decomposition studies were performed at an initial drug concentration 0.64 mg 
mL
−1 of T, 0.08 mg mL
−1 of A, 0.2 mg mL
−1 of H. The degradation conditions are selected 
on the basis of literature survey [13-17]. 
Water induced degradation 
Water hydrolysis was performed in purified at 60 °C for 6 hours. Fig. 5a shows the major 
degradation found at RRT 0.83 with respect to H. and all the major and minor degradation 
products were well separated from T, A, and H peaks. The peak purity is checked for T, A, 
and H and the results are summarized in Table 2. 
Hydrogen peroxide induced degradation 
For hydrogen  peroxide-induced degradation, the studies were carried out at room 
temperature in 1% hydrogen peroxide for 6 hours. The Fig.5a. shows the major 
degradation found at RRT 0.841 with respect to H and at RRT 1.056 and 1.272 with 
respect to A. All the major and minor degradation products were well separated from T, A, 
and H peaks. The peak purity is checked for T, A, and H and the results are summarized 
in Table 2. 
Acid induced degradation 
Acid hydrolysis was performed in 1N HCl at 60 °C for 6 hours. Fig. 5a shows the major 
degradation found at RRT 0.842 with respect to H. and all the major and minor   Rapid Simultaneous Determination of Telmisartan, Amlodipine Besylate and Hydrochlorothiazide …  79 
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degradation products were well separated from T, A, and H peaks. The peak purity is 
checked for T, A, and H and the results are summarized in Table 2.  
Base induced degradation  
The study in basic solution was carried out in 0.1N NaOH at 60 °C for 6 hours. The Fig. 
5b. shows all the three T, A, and H were stable in 0.1N NaOH and all the minor 
degradation products were well separated from T, A, and H peaks. The peak purity is 
checked for T, A, and H and the results are summarized in Table 2  
 
Fig. 5a.  Typical chromatograms of Telmisartan, Amlodipine besylate and Hydrochloro-
thiazide at 271 nm and 237 nm for force degradation study 
Heat induced degradation  
The drug product was exposed to dry heat at 105  °C for 24 hours. Samples  were 
withdrawn at appropriate time and subjected to UPLC analysis after suitable dilution (0.032 
mg mL
−1 of T, 0.004 mg mL
−1 of A, 0.01 mg mL
−1 of H).The Fig. 5b. shows that the drug 
product containing T, A, and H is thermally stable. The peak purity is checked for T, A, and 
H and the results are summarized in Table 2. 80 S.  Nalwade  et al.:  
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Photo-degradation  
Photo degradation studies were carried out at according to option 2 of Q1B in ICH 
guidelines [3]. Samples were exposed to light for an overall illumination of 1.2 million lux 
hours and an integrated near ultraviolet energy of 200 watt hm
2. Samples were withdrawn 
at appropriate time and subjected to UPLC analysis after suitable dilution (0.032 mg mL
−1 
of T, 0.004 mg mL
−1 of A, 0.01 mg mL
−1 of H). The drugs T, A and H are stable under 
photolytic condition. The peak purity is checked for T, A, and H and the results are 
summarized in Table 2. 
 
Fig. 5b.  Typical chromatograms of Telmisartan, Amlodipine besylate and Hydrochloro-
thiazide at 271 nm and 237 nm for force degradation study 
Linearity 
Linearity solutions were prepared from stock solution at six concentration levels from 50 to 
150% of analyte concentrations (16 to 48 µg mL
−1 for T, 2 to 6 µg mL
−1A and 5 to 15 µg 
mL
−1 for H). The linear regression analysis of T, A, and H were constructed by plotting the 
peak area of the analytes (y) versus analytes concentration in (x) axis. The calibration 
curves were linear in the range of 16 to 48 µg mL
−1 for T, 2 to 6 µg mL
−1A and 5 to 15 µg 
mL
−1 for H with a correlation coefficient of more than 0.999 for all the three drugs. The 
slope, Y-intercept and correlation coefficient were calculated and summarized in Table 3. 
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Precision  
The precision of the assay method was evaluated by carrying out six independent assays 
of T, A and H (0.032 mg mL
−1 of T, 0.004 mg mL
−1 of A, 0.01 mg mL
−1 of H) test samples 
against qualified reference standard. The percentage of RSD of six assay values was 
calculated. Different analyst from the same laboratory evaluated the intermediate precision 
of the method. The R.S.D. values of intra- and inter-day studies for T, A, and H confirming 
good precision of the method (Table 4).  
Tab.1.  System suitability parameters for T, A and H  
System suitability test parameters  T  A  H 
Retention time(min) 
(mean ± S.D., n = 5) 
3.944 
± 0.0018 
3.332 
± 0.0010 
0.913 
± 0.001 
Repeatability of retention time;  
R.S.D. % (n = 5)  0.0460 0.0300  0.3342 
Repeatability of peak area; 
R.S.D.% =(S.D./mean) x 100  0.1501 0.5403  0.0752 
Resolution (Rs)  8.3  36.9  – 
Tailing factor (asymmetric factor)  1.2  1.2  1.4 
Retention factor(k’) 2.944  2.332  0.082 
USP plate count  34765  43314  2974 
 
Tab. 2.  Peak purity results of T, A and H 
Purity Angle  Purity Threshold  Purity Flag Stress Condition 
T A H T A H  T  A  H 
Heat Stress  0.070  1.118 0.114 0.538 4.580 1.140 No No No
Aqueous Stress  0.057  0.902 0.131 0.499 3.973 1.384 No No No
Acid Stress  0.064  1.108 0.108 0.493 4.301 1.125 No No No
Base Stress  0.065  1.306 0.122 0.536 5.057 1.212 No No No
Peroxide Stress  0.060  1.727 0.241 0.533 5.776 1.202 No No No
 
Tab. 3.   Linearity 
Analyte  Concentration  
range  r
a Slope  intercept 
95% confidence 
interval for 
intercept 
Potential 
assay 
bias 
T  16.024–48.073  
µg.ml
−1  0.9999 6282.0  −888.486  877.9552 & 
−2656.9267  −0.4 
A  2.020–6.020  
µg.ml
−1  0.9996 10044.1   −14.5193 596.3377 & 
−625.3762   0.0 
H  5.000–15.000  
µg.ml
−1  0.9998 13499.7 −827.248  2710.7834 & 
−4365.2787  −0.6 
a Correlation coefficient. 
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Accuracy 
The accuracy of an analytical method expresses the nearness between the reference 
value and found value. The accuracy of the method was evaluated in triplicate at three 
concentration levels, i.e. 50%, 100% and 150% of target test concentration (0.64 mg mL
−1 
of T, 0.08 mg mL
−1 of A, 0.2 mg mL
−1 of H) in tablets. The results obtained are shown in 
Table 5. 
Tab. 4.   Intra-day and inter-day Precision results of T, A and H from tablets (n = 6) 
Pre-1 Pre-2 Pre-3 Pre-4 Pre-5 Pre-6    Active  
Name  % Assay 
% RSD  % Mean
T  100.2   99.7 100.2 100.4  99.4  100.6  0.45  100.1 
A   99.0   99.3   98.6   99.4 101.2   99.2  0.90    99.5  Intra-day  
precision  H   98.9   98.8   99.3   99.9 100.1   99.8  0.54    99.5 
T    98.0 100.0 100.9   99.0  99.3  100.4  1.04   99.6 
A   99.9   99.4   98.4   99.4   99.8   99.4  0.53   99.4  Inter-day  
precision 
H  100.0 100.6 100.6   99.7 100.0   99.3  0.51  100.0 
 
Tab. 5.  Accuracy Results of T, A and H from tablets (n = 6) 
Analyte  Recovery 
level 
Actual  
Conc. 
(µg.ml
−1) 
Found Conc.
(µg.ml
−1)  % Recovery % R.S.D.  % Error
a
 50%  320  321.86±0.567 100.58 0.564    0.581 
100% 640  640.51±0.449 100.08 0.449    0.080  T 
150% 960  964.51±0.638 100.47 0.635    0.470 
 50%   40   39.99±0.480  99.97  0.480  −0.030 
100%   80   79.56±0.903  99.45  0.908  −0.550  A 
150% 120  119.78±0.194   99.82 0.194  −0.183 
 50%  100  993.2±0.492   99.32  0.495  −0.683 
100% 200  198.94±0.547   99.47 0.549  −0.530  H 
150% 300  298.50±0.297   99.50 0.298  −0.750 
a [found conc. – actual conc./actual conc.] x 100. 
 
Solution Stability and Mobile Phase Stability  
The solution stability of T, A and H was carried out by leaving the test solution in tightly 
capped volumetric flask at room temperature for 48 hrs. The same sample solution was 
assayed for a 24 hours interval up to the study period against freshly prepared standard 
solution of T, A and H. The mobile phase stability was also carried out by assaying the 
freshly prepared standard solution for 24 hours interval up to 48 hours. The mobile phase 
preparation was kept constant during the study period. The percentage RSD of assay of T, 
A and H was calculated for the study period during mobile phase and solution stability 
experiments. The % RSD of the assay of T, A, and H during solution stability and mobile 
phase experiments were within 1% and it indicates that both standard and test preparation 
and mobile phase were stable for 2 days on bench top at room temperature.   Rapid Simultaneous Determination of Telmisartan, Amlodipine Besylate and Hydrochlorothiazide …  83 
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Conclusions 
The established UPLC method proves to be simple, linear, precise, accurate and specific. 
The total runtime was 4.5 minutes within which three drugs and their degradation products 
were separated. The method was validated and shows satisfactory data for all the method 
validation parameters tested. The Developed method is stability indicating and can be 
used for simultaneous quantitative determination of the drugs T, A and H in presence of 
degradation products in stability by the industry. The adopted UPLC method also can be 
used separately for assay estimation of Telmisartan tablets, simultaneous estimation of 
Telmisartan and Hydrochlorothiazide tablets and simultaneous estimation of Amlodipine 
besylate and Hydrochlorothiazide tablets. 
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